Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of ELA026 in Healthy Adults
NCT05556863Phase 1Completed
- Sponsor
- Electra Therapeutics
- Start
- Oct 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ELA026 in haemophagocytic lymphohistiocytosis (HLH) (3 arms), sponsored by Electra Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events. Started Oct 2021; status: completed.
02
Drugs
ELA026
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05556863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556863.